Lumexa Imaging Holdings earnings release, May 12, 2026

Lumexa Imaging Holdings, Inc. (LMRI) · Form 8-K, Item 2.02 · Filed · SEC filing

Lumexa Imaging Announces First Quarter 2026 Results

RALEIGH, NORTH CAROLINA, May 12, 2026—Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced results for the first quarter ended March 31, 2026, and reiterated full year 2026 guidance.

“In Q1, we delivered several meaningful achievements to kick off a year of executing on our strategic priorities.” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “We continued to drive strong growth in same-center advanced imaging volumes and our de novo centers are ramping according to our plans.”

“We are also announcing tonight four additional Lumexa Imaging centers including two strategic tuck-in acquisitions plus two de novos. We are well on our way to achieving our stated goal of adding

8-10 de novos to our network of centers this year.” Ms. Zulla continued, “With a large addressable market, and strong demand tailwinds plus a focused strategy centered on same-center growth, geographic expansion, and advanced imaging, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors.”

First Quarter 2026 Highlights:

All comparisons are to the quarter ended March 31, 2025, unless otherwise noted

Outpatient Volumes:

Note: Advanced Procedures includes MRI and CT modalities

2026 Full Year Outlook:

The company is reiterating its outlook for the year ending December 31, 2026. Lumexa Imaging continues to expect:

Lumexa Imaging Earnings Conference Call and Webcast

Lumexa Imaging will host a conference call to discuss its first quarter 2026 results, as well as its 2026 outlook, on May 12, 2026 at 5:00 p.m. ET. The call can be accessed via live audio webcast online at ir.lumexaimaging.com. A replay of the webcast will be available at the same link shortly after the completion of the call and will remain available for approximately one year.

Statement Regarding Use of

Non-GAAP

Financial Measures

This press release uses Adjusted EBITDA and Adjusted EPS, financial measures that are not calculated in accordance with GAAP. We use Adjusted EBITDA and

Adjusted EPS, in conjunction with GAAP financial measures, as an integral part of managing our business and to, among other things: (i) monitor and evaluate the performance of our business operations and financial performance;

(ii) facilitate internal comparisons of the historical operating performance of our business operations; (iii) review and assess the operating performance of our management team; and (iv) analyze and evaluate financial and strategic planning decisions regarding future operations and annual operating budgets. For a reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable measure calculated in accordance with GAAP, please see below.

We have not reconciled our Adjusted EBITDA or Adjusted EPS guidance to their most directly comparable GAAP measures because we do not and are not able to provide guidance for those GAAP measures due to the uncertainty and potential variability of certain reconciling items, including transaction costs, severance and executive recruiting. Because such items cannot be provided without unreasonable efforts, we are unable to provide the corresponding reconciliations. However, such reconciling items could have a significant impact on our future results.

About Lumexa Imaging

Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and greater than 190 outpatient imaging centers, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.

Financial statements

Income Statement

Three Months Ended March 31, — (Unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
REVENUES:Net patient service revenue197,318192,298
REVENUES:Management fee and other revenue55,21952,703
REVENUES:Total revenues252,537245,001
OPERATING EXPENSES:Cost of operations, excluding depreciation and amortization217,755208,397
OPERATING EXPENSES:General and administrative expenses20,33517,492
OPERATING EXPENSES:Depreciation and amortization9,9229,051
OPERATING EXPENSES:Loss on disposal of property and equipment137-162
OPERATING EXPENSES:Total operating expenses248,149234,778
OPERATING EXPENSES:Equity in earnings of unconsolidated affiliates15,02415,318
OPERATING EXPENSES:INCOME FROM OPERATIONS19,41225,541
OTHER EXPENSES:Interest expense16,33129,849
OTHER EXPENSES:INCOME (LOSS) BEFORE INCOME TAXES3,081-4,308
OTHER EXPENSES:Income tax provision1,3643,379
OTHER EXPENSES:NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)1,717-7,687
Weighted average shares outstanding:Basic95,983,23369,523,369
Weighted average shares outstanding:Diluted95,983,24369,523,369
Net income (loss) per common shareBasic0.02-0.11
Net income (loss) per common shareDiluted0.02-0.11

Income Statement

Three Months Ended March 31, — (Unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net income (loss)1,717-7,687
Depreciation and amortization9,9229,051
Income tax provision1,3643,379
Amortization of basis difference531500
Interest expense16,33129,849
Stock-based compensation12,2746,374
Loss on disposal of property and equipment137-162
Severance and executive recruiting(1)9451,370
Strategic initiatives and implementation(2)825868
Transaction costs(3)2,5823,588
Litigation and settlements(4)29-128
Other(5)-522
Adjustments for equity in earnings of unconsolidated affiliates(6)4,5473,975
Adjusted EBITDA51,19950,999

Income Statement

Three Months Ended March 31, — (Unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Components of “management fee and other revenues:”Fees for managing joint ventured outpatient sites and other third party services21,49820,076
Components of “management fee and other revenues:”Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa33,72132,627
Components of “management fee and other revenues:”Total revenues55,21952,703

Balance Sheet

March 31, 2026 — (Unaudited) (in thousands)

March 31, 2026December 31, 2025
ASSETSCash and cash equivalents51,22658,828
ASSETSAccounts receivable118,141112,942
ASSETSAccounts receivable, related party15,94218,893
ASSETSOther receivables20,04519,015
ASSETSPrepaid expenses16,53417,582
ASSETSTotal current assets221,888227,260
ASSETSProperty and equipment, net of accumulated depreciation150,127144,709
ASSETSOperating lease right-of-use assets76,17576,555
ASSETSInvestments in unconsolidated affiliates420,519423,191
ASSETSIntangible assets, net of accumulated amortization40,24541,335
ASSETSGoodwill807,554807,554
ASSETSOther assets46,84543,953
ASSETSTOTAL ASSETS1,763,3531,764,557
LIABILITIES AND EQUITYAccounts payable37,16844,857
LIABILITIES AND EQUITYAccrued expenses and other current liabilities80,17495,561
LIABILITIES AND EQUITYAccounts receivable pledging arrangement1,6931,599
LIABILITIES AND EQUITYCurrent portion of long-term debt13,43713,112
LIABILITIES AND EQUITYCurrent portion of finance lease liabilities13,40811,552
LIABILITIES AND EQUITYCurrent portion of operating lease liabilities12,05312,513
LIABILITIES AND EQUITYTotal current liabilities157,933179,194
LIABILITIES AND EQUITYLong-term debt, less current maturities816,974819,029
LIABILITIES AND EQUITYLong-term finance lease liabilities, less current maturities38,48333,262
LIABILITIES AND EQUITYLong-term operating lease liabilities, less current maturities71,40271,437
LIABILITIES AND EQUITYDeferred income taxes41,49840,772
LIABILITIES AND EQUITYOther liabilities37,44334,740
LIABILITIES AND EQUITYTotal liabilities1,163,7331,178,434
EQUITY:Common stock, $0.001 par value, 1,000,000,000 shares authorized, 96,080,735 shares issued and outstanding at March 31, 2026 and 96,109,927 shares issued and outstanding at December 31, 20259696
EQUITY:Additional paid-in-capital1,228,8671,217,087
EQUITY:Accumulated deficit-629,343-631,060
EQUITY:Total equity599,620586,123
EQUITY:TOTAL LIABILITIES AND EQUITY1,763,3531,764,557

Cash Flow

Three Months Ended March 31, — (Unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)1,717-7,687
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesDepreciation and amortization9,9229,051
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesAmortization of operating lease right-of-use assets3,9573,739
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesAmortization of debt issuance costs7171,433
Adjustments to reconcile net income (loss) to net cash provided by operating activitiesAmortization of cloud computing implementation costs161113
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,”

“intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our guidance for full year 2026 and our assumptions underlying such guidance; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including but not limited to those risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our Annual Report on Form

10-K for the year ended December 31, 2025, each as filed with the Securities and Exchange Commission (SEC). The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any... (truncated)ate any forward-looking statements, except as required by law.

Investors:

Sue Dooley

Lumexa Imaging sue.dooley@Lumexaimaging.com

Media Contact

Melissa Weston

Lumexa Imaging

Melissa.Weston@LumexaImaging.com

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Lumexa Imaging Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.